"Large-vessel vasculitis following the Pfizer-BioNTech COVID-19 vaccine": comment

Pathum Sookaromdee¹ · Viroj Wiwanitkit²

Received: 26 January 2022 / Accepted: 5 February 2022 / Published online: 27 February 2022
© The Author(s), under exclusive licence to Società Italiana di Medicina Interna (SIMI) 2022

Dear Editor,

We would like to share ideas on the publication "Large-vessel vasculitis following the Pfizer-BioNTech COVID-19 vaccine [1]". Gilio and De Stefano mentioned that "*The pathogenesis of post-vaccination vasculitis remains unclear. To our knowledge, this is the first report of large vessel vasculitis following by BNT162b2 vaccination..... [1].*" We concur that COVID-19 vaccination can have negative consequences, with large-vessel vasculitis being one example. However, as Gilio and De Stefano pointed out, no clear pathophysiology has been provided in this case. Atypical immunological responses are frequently cited as a source of several of the COVID-19 vaccine's side effects. There is also no information on the patient's immunological status or vascular health prior to vaccination. We should be aware that large-vessel vasculitis in a COVID-19 vaccination recipient could be caused by an underlying disease or a concomitant medical issue. Dengue fever could emerge in a vaccine recipient as an example of a concomitant medical illness [2]. Dengue is also a possible cause of large vessel vasculitis [3].

Author contributions PS: substantial contributions to study conception and design, substantial contributions to acquisition of data, substantial contributions to analysis and interpretation of data, drafting the article or revising it critically for important intellectual content, final approval of the version of the article to be published. VW: substantial

contributions to study conception and design, substantial contributions to acquisition of data, substantial contributions to analysis and interpretation of data, drafting the article or revising it critically for important intellectual content, final approval of the version of the article to be published.

Declarations

Conflict of interest The author(s) declare that they have no conflict of interest.

Statements on human and animal rights and Informed consent This is a correspondence on published article and does not involve with any human or animal subjects. Ethical approval and informed consent are not required.

References

1. Gilio M, De Stefano G (2022) Large-vessel vasculitis following the Pfizer-BioNTech COVID-19 vaccine. Intern Emerg Med. <https://doi.org/10.1007/s11739-021-02908-4> (Online ahead of print)
2. Kebayoon A, Wiwanitkit V (2021) Dengue after COVID-19 vaccination: possible and might be missed. Clin Appl Thromb Hemost. <https://doi.org/10.1177/10760296211047229>
3. Jose A, Dhar M, Panda PK, Kishore S (2021) Expanded dengue syndrome with small-medium-vessel vasculitis: a case report. Int J Crit Illn Inj Sci 11(1):39–42

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

✉ Pathum Sookaromdee
pathumsook@gmail.com

¹ Private Academic Consultant, Bangkok, Thailand

² Dr DY Patil University, Pune, India